EDUARDO
DÍAZ-RUBIO GARCÍA
Forscher bis um 2020
M. A.
Gómez España
Publikationen, an denen er mitarbeitet M. A. Gómez España (16)
2023
2022
-
Upfront primary tumour resection and survival in synchronous metastatic colorectal cancer according to primary tumour location and RAS status: Pooled analysis of the Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
European Journal of Surgical Oncology, Vol. 48, Núm. 5, pp. 1123-1132
2021
-
First-Line Biological Agents Plus Chemotherapy in Older Patients with Metastatic Colorectal Cancer: A Retrospective Pooled Analysis
Drugs and Aging, Vol. 38, Núm. 3, pp. 219-231
2019
2018
2012
-
Circulating tumor cell count is a prognostic factor in metastatic colorectal cancer patients receiving first-line chemotherapy plus bevacizumab: A spanish cooperative group for the treatment of digestive tumors study
Oncologist, Vol. 17, Núm. 7, pp. 947-955
-
First-Line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: The phase III MACRO TTD study
Onkologie, Vol. 6, Núm. 2, pp. 96-103
-
First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: The phase III MACRO TTD study
Oncologist, Vol. 17, Núm. 1, pp. 15-25
-
Role of Kras Status in Patients with Metastatic Colorectal Cancer Receiving First-Line Chemotherapy plus Bevacizumab: A TTD Group Cooperative Study
PLoS ONE, Vol. 7, Núm. 10
2011
-
Recommendations and expert opinion on the treatment of locally advanced rectal cancer in Spain
Clinical and Translational Oncology, Vol. 13, Núm. 12, pp. 862-868
-
Treatment recommendations for metastatic colorectal cancer
Clinical and Translational Oncology, Vol. 13, Núm. 3, pp. 162-178
2009
-
Elderly patients with advanced colorectal cancer derive similar benefit without excessive toxicity after first-line chemotherapy with oxaliplatin-based combinations: Comparative outcomes from the 03-TTD-01 phase III study
Critical Reviews in Oncology/Hematology, Vol. 70, Núm. 2, pp. 134-144
-
Randomized study of weekly irinotecan plus high-dose 5-fluorouracil (FUIRI) versus biweekly irinotecan plus 5-fluorouracil/leucovorin (FOLFIRI) as first-line chemotherapy for patients with metastatic colorectal cancer: A Spanish Cooperative Group for the Treatment of Digestive Tumors Study
Annals of Oncology, Vol. 20, Núm. 2, pp. 251-257
2008
-
Pharmacogenetic approach for capecitabine or 5-fluorouracil selection to be combined with oxaliplatin as first-line chemotherapy in advanced colorectal cancer
European Journal of Cancer, Vol. 44, Núm. 9, pp. 1229-1237
2007
-
Phase III study of capecitabine plus oxaliplatin compared with continuous-infusion fluorouracil plus oxaliplatin as first-line therapy in metastatic colorectal cancer: Final report of the Spanish Cooperative Group for the treatment of digestive tumors trial
Journal of Clinical Oncology, Vol. 25, Núm. 27, pp. 4224-4230
2006
-
UFT in combination with oxaliplatin: Clinical phase I study in patients with advanced or metastatic solid tumors
Anti-Cancer Drugs, Vol. 17, Núm. 4, pp. 417-421